|
|
|
|
|
The Niche Stem Cell & Regen Med Website
|
We have a new post today!
|
|
|
Weekly reads: Sarepta, epigenomics, FDA on eyedrops
|
|
|
|
The biotech Sarepta has had a complicated go of it with the FDA sometimes related to their Duchenne muscular dystrophy (DMD) gene therapy efforts. In late 2016 I wrote about how there was some controversy as the FDA approved the Sarepta drug eteplirsen (Exondys 51) also for DMD, going against an advisory panel that had recommended against approval. Now STAT …
|
|
|
|
|
|
|
